The emerging therapeutic potential of the oncolytic immunotherapeutic Pexa-Vec (JX-594)
Oncolytic Virotherapy · 2015-01 · 25
DOI: 10.2147/ov.s59640 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Oncolytic Virotherapy, 2015-01. Verfasst von Caroline J Breitbach und 4 weiteren Autor:innen. Beteiligte Einrichtung: SillaJen Inc, Seoul, South Korea. Die Arbeit wurde bisher 52-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Oncolytic immunotherapeutics (OIs) are viruses designed to preferentially replicate in and lyse cancer cells, thereby triggering antitumor immunity. Numerous oncolytic platforms are currently in clinical development. Here we review preclinical and clinical experience with Pexa-Vec (pexastimogene devacirepvec, JX-594). Pexa-Vec is derived from a vaccinia vaccine strain that has been engineered to target cancer cells and express the therapeutic transgene granulocyte macrophage colony-stimulating factor (GM-CSF) in order to stimulate antitumor immunity. Key to its ability to target metastatic disease is the evolution of unique vaccinia virus characteristics that allow for effective systemic dissemination. Multiple mechanisms of action (MOA) for Pexa-Vec have been demonstrated in preclinical models and patients: 1) tumor cell infection and lysis, 2) antitumor immune response induction, and 3) tumor vascular disruption. This review will summarize data on the Pexa-Vec MOA as well as provide an overview of the Pexa-Vec clinical development program from multiple Phase I studies, Phase II studies in renal cell cancer and colorectal cancer, through Phase IIb clinical testing in patients with advanced hepatocellular carcinoma (primary liver cancer).
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- SillaJen Inc, Seoul, South Korea.
- Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, ON, Canada; Centre for Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, ON, Canada.
Zitieren
APA
Breitbach, C. J., Bell, J. C., Hwang, T. H., Kirn, D. H., & Burke, J. (2015). The emerging therapeutic potential of the oncolytic immunotherapeutic Pexa-Vec (JX-594). Oncolytic Virotherapy, 25. https://doi.org/10.2147/ov.s59640
Vancouver
Breitbach CJ, Bell JC, Hwang TH, Kirn DH, Burke J. The emerging therapeutic potential of the oncolytic immunotherapeutic Pexa-Vec (JX-594). Oncolytic Virotherapy. 2015:25. doi:10.2147/ov.s59640
BibTeX
@article{Breitbach2015,
author = {Breitbach, Caroline J and Bell, John C and Hwang, Tae-Ho and Kirn, David H and Burke, James},
title = {The emerging therapeutic potential of the oncolytic immunotherapeutic Pexa-Vec (JX-594)},
journal = {Oncolytic Virotherapy},
year = {2015},
pages = {25},
doi = {10.2147/ov.s59640}
}
EUVIMED